Jennifer moderated a session at IPBC China hosted by IAM on the latest developments of European IP. Other panel members included Clemens Heusch, head of global litigation at Nokia, and Tum Thach, Senior IP Counsel at Airbus. Topics discussed included Brexit’s impact on European patent strategy, the UPC which is finally about to come into effect, FRAND licensing, and anti-suit injunctions.
我们的过去活动
Recommended Insights
FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement
2023年1月4日Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]
阅读更多 >
CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants
2023年4月12日At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]
阅读更多 >
China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results
2022年6月30日China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
阅读更多 >
Compositions Limited by Use: A Cautionary Tale
2022年10月26日Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
阅读更多 >